

Disclaimer

Acknowledgement: For the purposes of this notice, "Presentation" shall mean and include this document, any oral presentation of this document by any person, any question-and-answer session, hard copies of this document and any materials distributed at any such presentation or in connection with this document. By attending the meeting at which the Presentation is made, dialing into the teleconference during which the Presentation is made or reading, accessing or making any other use of the information made available in this Presentation, you acknowledge and irrevocably represent that you have read and understood these terms and conditions and you voluntarily and irrevocably accept and agree to be bound by them.

Purpose: Spa Holdings 3 Oy and its group companies (collectively, the "Company", "we" or "our") has prepared this presentation and the information contained herein for general informational purposes only. This Presentation is being made available on a confidential basis to existing and prospective lenders and noteholders, securities analysts, rating agencies and other eligible persons in connection with the reporting requirements under our principal financing arrangements. This Presentation may not be used for any other purpose.

No Offer: None of the information made available in this Presentation constitutes or forms part of, and is not made in connection with, any offer, invitation or recommendation to subscribe for, underwrite or otherwise acquire any securities of the Company or any of its affiliates, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any security, nor shall it or any part of it form the basis of or be relied upon as investment, legal, accounting, tax or other professional advice or in connection with any offer or sale of securities or any contract or commitment whatsoever. Any securities referred to herein have not been and will not be registered under the U.S. Dersons that are outside to 1913, as a mended (the "Securities Act") and may be offered or sold only to investors who are either (i) qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) in the United States or (ii) non-U.S. persons that are outside the united States and who are acquiring such securities in offshore transactions in reliance on Regulation S under the Securities Act, provided that investors resident in a Member State of the European Economic Area ("EEA") or the United Kingdom are not retail investors. For these purposes, a "retail investor" means: (a) in the EEA, a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of MiFID II; or (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended from time to time, the "Insurance Mediation Directive"), where that customer would not qualify as a professional client as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("EUWA"); or (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 ("FSMA") and any rules or regulations made under the FSMA to implement the Directive (EU) 2016/97, where tha

You must comply with all laws that apply to you in any place in which you buy, offer or sell any securities or access or possess the content contained in this Presentation. If you access this Presentation, you must inform yourself about and observe any such restrictions and seek appropriate independent professional advice where necessary.

Neither this Presentation nor any of its consents has been filed with or reviewed by the U.S. Securities and Exchange Commission or any other governmental or self-regulatory authority. Investments in securities involve numerous risks, including but not limited to market, currency, economic, regulatory, tax, political, business and other risks. There can be no guarantee that an investment in securities will be profitable, or that investors in securities will not lose some or all of their investment.

Forward-Looking Statements: Certain statements contained in this Presentation may be statements of future expectations and other forward-looking statements. The forward-looking statements include, but are not limited to, all statements other than statements of historical facts, including, without limitation, those regarding the Company's future financial position and results of operations, strategy, plans, objectives, goals and targets and future developments in the markets where the Company participates or is seeking to participate. You can identify these forward-looking statements by the use of words such as "aim," "anticipate," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "objectives," "ongoing," "outlook," "plan," "potential," "predict," "probably," "project," "seek," "should," "target," "will," "would" or the negative version of these words or similar expressions. Any forward-looking statements in this Presentation are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause the Company's actual results and performance to differ materially from any expected future results or performance expressed or implied by any forward-looking statements. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements as a result of new information, future developments or otherwise. The information and opinions contained in this Presentation are provided as at the date stated herein and are subject to change without notice. This Presentation will not be updated to reflect any subsequent development and may be superseded or otherwise modified by subsequent releases or other updates.

No Representation or Warranty: Neither the Company nor any of its affiliates makes any representation or warranty or other assurance, express or implied, that this Presentation or the information contained herein or the assumptions on which they are based are accurate, complete, adequate, fair, reasonable or up to date and they should not be relied upon as such. Neither the Company nor any of its affiliates accepts any liability for any loss or damage (including any direct, indirect or consequential loss or damages) suffered by any person as a result of relying on all or any part of this document and any liability is expressly disclaimed.


While the Company uses reasonable efforts to obtain information from reliable sources, the Company makes no representations or warranties as to the accuracy, reliability or completeness of any information or document in this Presentation obtained from outside sources. Unsourced statements should be understood to reflect the subjective beliefs, opinions, expectations or understandings of the Company, which may be inaccurate.

Market and Industry Data: To the extent applicable, the industry and market data contained in this document has come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the fairness, quality, accuracy, relevance, completeness or sufficiency of such data. We have not independently verified the data contained therein. In addition, certain of the industry and market data contained in this document come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. Such research and estimates, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this document. Although the Company has obtained such information provided from sources that should be considered reliable, it cannot guarantee its accuracy or completeness. The information provided is purely of an indicative nature and is subject to change without notice at any time.



Business highlights Q2/2021


- Improved comparable EBITDA and margin
- Sales volumes rose in nearly all businesses as customer activity continued to improve
- Sales prices were raised during the second quarter, offsetting a large part of the rapidly increased raw material costs
- EUR 58 million investment decision in a new glass fiber tissue production line in the U.S. to better serve the North American market
- Good progress in transformation initiatives






Solid volumes in Q2

- improvement from pre-pandemic levels





Accelerating value creation through major investment in the Glass Fiber Tissue business

- New glass fiber tissue production line in Madisonville plant, the US, to further strengthen global leadership position
- Full range of high-quality and cost competitive glass fiber tissue with focus on Luxury Vinyl Tiles and Vinyl sheet materials
- Provides additional capacity and allows better service regionally for the flooring industry in North America
- Customer deliveries starting in mid-2023
- Based on state-of-the-art foam forming technology with low environmental footprint, consuming less water and energy
- Creates some 50 new job opportunities locally
- Accelerates value creation by strengthening our strongholds





Filtration & Performance Solutions

Glass Fiber Tissue

Demand drivers

- Construction and renovation activity
- Growing popularity of luxury vinyl tile flooring solutions, especially in North America
- Substitution from other flooring reinforcements such as mineral felt, especially in North America


Strengths

- Unique glass fiber tissue production technology
- Agile customer service and close customer relationships
- In-depth industry knowledge in flooring applications and in other glass veil application

Going forward


 Further strengthen global leadership in glass fiber tissue for flooring applications and expand portfolio of applications for glass fiber tissue The **Glass Fiber Tissue** business produces glass fiber tissue, mainly for flooring applications, and a range of building and transportation related end-uses. In flooring applications, Ahlstrom-Munksjö targets global markets.

- Market position #1 in flooring
- Average market growth 3-8% p.a.



Higher sales volumes boosted net sales

Net sales Q2/21 vs Q2/20




Net sales impacted by:

- Higher sales volumes in nearly all businesses
- Mix improvement driven by filtration, glass fiber tissue, nonwovens, specialty release liners and life science related products
- Adverse FX mainly driven by weaker
 USD

Comparable EBITDA improved due to increased volumes


Comparable EBITDA Q2/21 vs Q2/20



EBITDA impacted by:

- Higher sales volumes
- Cost efficiency measures partly offsetting rapid increase in raw material costs
- Fixed costs increased from an exceptionally low level in the previous year and due to a high production level

Breakdown of operating costs 2020



- Rapidly increasing raw material prices and costs during first half of 2021
- Cost saving initiatives to mitigate cost inflation



Energy 8%

Reconciliation of comparable EBITDA to adjusted EBITDA (last twelve months)

MEUR		
Comparable EBITDA pro forma		372.0
Proforma foreign exchange impact	-0.1	
Comparable EBITDA		371.9
One off and other adjustements	2.1	
COVID-19 normalization	2.4	
Full year estimate of 2020 initiatives	5.0	
Full year 2021 initiatives	54.1	
Full year 2022 initiatives	18.8	
Adjusted EBITDA		454.3

Adjusted EBITDA (LTM) remained on the same level as at the end of Q1/2021 and was impacted by:

- Higher comparable EBITDA
- Covid-19 normalization
- Realization of some of the expected savings from the FY 2021 initiatives



Reported cash flow and financing in Q2/2021

MEUR	Q2/2021	H1/2021
EBITDA	77.6	101.2
Change in net operating working capital	11.2	-37.4
Interest paid	-32.2	-42.8
Taxes paid	-15.6	-18.0
Adjustments, other	-8.0	-11.1
Net cash from operating activities	33.0	-8.1
Acquisition of Ahlstrom-Munksjö	-	-1,577.4
Capital expenditure excluding acquisitions	-31.9	-47.9
Other	0.3	0.4
Net cash from investing activities	-31.6	-1,624.9
Equity contribution	-	1,084.6
Repayment of borrowings	-296.5	-920.8
Proceeds from borrowings	44.1	1,689.8
Other	-8.2	-69.9
Net cash from financing activities	-260.6	1,783.5
Net change in cash and equivalents	-259.1	150.5

Items affecting comparability (IAC) and other items totaled EUR -18.2 million in Q2/21 and EUR -65.6 million in H1/21

Seasonal increase in working capital mitigated by increased factoring in Q2/21

Free cash flow EUR 146.7 million and cash conversion 87% in Q2/21


Stable net indebtedness of EUR 1,731 million and net indebtedness to adjusted EBITDA ratio 3.8



Debt structure as of June 30, 2021

- Financing of the Ahlstrom-Munksjö acquisition
 - Senior secured term facilities and two secured notes, maturing in 2028
- Assumed EUR 1,159 million of Ahlstrom-Munksjö Oyj debt mainly refinanced and repaid
 - EUR 100 million hybrid bond redeemed in July 2021
 - EUR 250 million unsecured notes redeemed in April 2021
- Cash and cash equivalents EUR 182 million on June 30, 2021
- Interest expense (LTM) EUR 88 million
- No major refinancing needs until 2027-28
- Renegotiated factoring facility to EUR 300 million

Interest-bearing liabilities as of June 30, 2021





Conclusions

- Comparable EBITDA and margin improved
- Sales prices were raised to offset rapidly increased raw material costs
- Investment decision to expand
 Glass Fiber Tissue business
- Good progress in transformation initiatives



